.Pharmacolibrary.Drugs.N_NervousSystem.N04C_OtherAntiparkinsonDrugs.N04CX01_Istradefylline.Istradefylline .Pharmacolibrary.Drugs.N_NervousSystem.N04C_OtherAntiparkinsonDrugs.N04CX01_Istradefylline.Istradefylline| name: | Istradefylline |
| ATC code: | N04CX01 | route: | oral |
| n-compartments | 2 |
Istradefylline is a selective adenosine A2A receptor antagonist used as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing 'off' episodes. It is currently approved for use in several countries including the United States.
Pharmacokinetic parameters in healthy adults after single oral administration.
Knebel, W, et al., & Chaikin, P (2011). Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. Journal of clinical pharmacology 51(1) 40–52. DOI:10.1177/0091270010363809 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20200269
Cabreira, V, et al., & Massano, J (2019). Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs 79(6) 593–608. DOI:10.1007/s40265-019-01098-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/30905034